A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT04088396 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Juvenile Idiopathic Arthritis

Interventions

DRUG: Baricitinib
DRUG: Tocilizumab

Sponsor

Eli Lilly and Company